Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2017/05/008531
CTRI/2017/05/008531CompletedPhase 3

Open Label, Multicenter, Randomized, Comparative study to Evaluate the efficacy and safety of drugs Forb 100 HFA (Generic name: Budesonide+Formoterol), metered dose aerosol for inhalation100+6 µg/dose (Midas Care Pharmaceuticals Pvt. Ltd., India) and Foradil Combi, set of capsules with inhalation powder 200+12 µg/caps (dose) (Novartis Pharma AG, Switzerland) in patients with partially controlled asthma

RUS Biopharm LLC0 sites116 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
116
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •1 The diagnosis of persistent BA,established in accordance with GINA,2015,atleast 6monthsprior to the screening visit.
  • •2 Need to use SABA more than 2 times per week.
  • •3 BA insufficently controlled by the inhaled gluco corticosteroids and short acting Betta 2 adrenoceptor agonists (SABA)as on demand therapy
  • •1 of 2 of the followings items required
  • •a) Daytime symptoms more often than 2 times a week.
  • •b) Night awakenings due to asthma.
  • •c) Need for medication to relieve symptoms more often than 2 times a week.
  • •d) Any activity limitation due to BA
  • •4 Patients with of asthma control test scores under the ACQ-5 questionnaire: more thyan or equal to 0.75 points and less than 1.5 points
  • •5 Forced expiratory volume per 1 second (FEV1) index before taking bronchial spasmolytics not less than 60% of the due.
  • •6 Positive response to the reversibility test, defined as Î?FEV1 more than or equal to 12% and more than or equal to 200 ml compared to baseline, through 30 minutes after taking 400 µg salbutamol.
  • •7 Patients should have used background therapy of BA with iGCS at low doses for at least 1 month prior to the screening visit
  • •Drug Daily dosage (µg)
  • •Beclomethasone dipropionate200â??500
  • •Budesonide 200â??400
  • •Fluticasone propionate 100â??250
  • •Mometasone furoate 110â??220
  • •Ciclesonide 80â??160
  • •8 Ability to correctly perform the technique of inhalations of the study product and daily peak flowmetry
  • •9 Patients consent to use reliable contraceptive methods throughout the study and within 3 weeks after it obtained from:
  • •a) women with negative pregnancy test and using the following methods of contraception:intrauterine devices, oral contraceptives with low doses of estrogen, barrier method and double barrier protection. Women of child-bearing potential (with a history of hysterectomy, tubal ligation, infertility, menopause for more than 1 year) may also participate in the study.
  • •b) Men using barrier methods of contraception. Men unable to procreate (with a history of vasectomy, infertility) may also participate in the study.
  • •10 Signed and dated informed consent to participate in the study.

Exclusion Criteria

  • •1.Patients requiring the selection of a starting maintenance therapy of BA.
  • •2.Contraindications to treatment with iGCS, hypersensitivity to Budesonide, Formoterol or any components of the study product and reference product.
  • •3.Lactase deficiency, lactose intolerance or glucose-galactose malabsorption.
  • •4.Body mass index (BMI) more than 35 kg per meter square.
  • •5.The diagnosis of COPD, established under the version of GOLD, 2015.
  • •6.Overuse of SABA more than 7 times per week or more than 8 inhalations per day for 2 consecutive days).
  • •7.Patients who received oral or parenteral glucocorticosteroids (GCS) within previous 2 months before the screening visit (3 months for parenteral GCS of prolonged action)
  • •8.Conditions, requiring systemic GCS.
  • •9.Unexpected and progressive deterioration of control over BA symptoms.
  • •10.History of bronchial asthma with almost fatal outcome (e.g unstable bronchial asthma, hospitalizations due to asthma exacerbation in the intensive therapy unit with the application of intubation).
  • •11.Pulmonary tuberculosis (active or inactive form).
  • •12.Fungal, viral or bacterial infections of the respiratory tract or systemic viral infections, herpetic lesion of the eye (Herpes simplex).
  • •13.Lower respiratory tract infection within 1 month before screening visit
  • •14.Cystic fibrosis, bronchiectasis, pneumoconiosis.
  • •15.Restrictive disorders of pulmonary ventilation.
  • •16.Uncontrolled hypokalemia, hypocalcaemia.
  • •17.Thyrotoxicosis.
  • •18.Osteoporosis.
  • •19.Glaucoma, cataract
  • •20.Ischemic heart disease, cardiac arrhythmia and conduction disorder, particularly, AV block III degree; chronic heart failure II, III, IV NYHA classes; idiopathic muscular subaortic stenosis; hypertrophic obstructive cardiomyopathy, aortic aneurysm; known or suspected QT interval prolongation.
  • •21.Diseases, manifesting with increased bleeding (hemorrhagic diathesis, haemophilia, thrombocytopenia, etc.) or conditions, associated with a high risk of bleeding.
  • •22.Impairment of adrenal function.
  • •23.Hepatic insufficiency syndrome, confirmed by objective examination and clinical and laboratory data.
  • •24.Severe, decompensated or unstable somatic diseases (any diseases or conditions, which threaten the patients life or impair the patients prognosis, and also render the participation of the patient in the clinical trial impossible).
  • •25.A history of other malignancies, except for patients in whom the disease was not observed in the last 5 years, patients with a fully cured basal cell carcinoma of the skin or fully cured carcinoma in situ.
  • •26.Administration of immunosuppressive drugs within 4 weeks prior to the study (e.g, cyclosporine, methotrexate, or TNF alpha-receptor antibodies or inhibitors, preparations of gold, azathioprine etc.).
  • •27.The need for drugs from the list of prohibited therapy.
  • •28.Smoking patients or those who smoked in the past more than 10 pack-years (pack-year: number of cigarettes, smoked per day, multiplied by the number of years of smoking per 20)
  • •29.History of alcohol or drug addiction, mental illness.
  • •30.Pregnancy, lactation period.
  • •31.The patients inability to abide by the terms of this Protocol.
  • •32.Participating in another clinical study during the last 3 months.
  • •33.Other conditions, which according the physician-investigator preclude

Investigators

Sponsor
RUS Biopharm LLC

Similar Trials

Not yet recruiting
Phase 3
Comparative Study of the Efficacy and Safety of Budesonide, Inhalation Powder, Capsule 400 μg/dose
CTRI/2017/02/007787Rus Biopharm LLC136
Recruiting
Phase 3
Efficacy and safety study to assess between two drugs (Inhaler) in patients with Chronic Obstructive Pulmonary Disease
CTRI/2023/01/048645upin Limited
Completed
Phase 2
Bladder Cancer Study.
CTRI/2007/091/000034Cadila Pharmaceuticals Ltd122
Active, not recruiting
Not Applicable
Trerief Impact in PD PET StudyParkinson's diseaseD010300
JPRN-jRCTs041180070Ouchi Yasuomi20
Completed
Not Applicable
Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) imagesParkinson's Disease
JPRN-UMIN000019524Hamamatsu University School of Medicine20